Already riding naloxone boom, Amphastar plots nasal spray to rival old formulas

A surge of opioid-related deaths in the U.S. has created an opportunity for pharma companies that make the overdose antidote naloxone. The drug's price has risen tenfold in recent years, Bloomberg reports, and state and local governments are shelling out to make it more widely available. One beneficiary? Amphastar Pharmaceuticals ($AMPH), which saw a 41% Q2 boost in revenue from its fully manufactured drugs. And the company is developing a ready-made naloxone nasal spray it hopes will pad its top line further. More

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.